<p>(A) Binding (<i>top</i>) and neutralizing (<i>bottom</i>) titers of the indicated macaque MAbs against the indicated Envs and viruses. (B) Antibody-binding competition. Top panels: The binding of the indicated macaque MAbs to the 426c NLGS-3 Core gp140 protein was determined in the absence of competing antibody <i>(left)</i>, or following the pre-incubation of 426c NLGS-3 Core gp140 with saturating concentrations of VRC01 <i>(middle left)</i>, CD4-IgG <i>(middle right)</i>, or b12 <i>(right)</i>. Bottom panels: Control experiments were performed with the indicated human MAbs. Direct binding of the indicated human MAbs to the 426c NLGS-3 Core gp140 protein (<i>left panel</i>), following the pre-incubation of Env with VRC01 (<i>second from...
Summary: Induction of broadly neutralizing antibodies (bnAbs) that target HIV-1 envelope (Env) is a ...
<p>(A) Sera collected at 10 days post-last vaccination were tested for neutralization of MERS-CoV in...
<p>(<b>a–c</b>) Human IgG1 antibody 503 (1 µg/mL) demonstrates binding to HEK-293 cells transiently ...
<p>A) FACS data overlay of individually sorted CVNbs-specific B cells (multicolored) from 4 SIV-infe...
<p><b>A</b>: Binding of Fab m43 to recombinant gp140s, gp120s and gp41Fc fusion protein. <b>B</b>: B...
Protection from immunodeficiency virus challenge in nonhuman primates (NHPs) by a first-generation H...
<p>Macaque samples (analyzed as purified IgG) are arranged in the left-most column according to the ...
<p><b>A.</b> Fusion loop-specific mouse MAb 4G2 was incubated at 1 µg/mL with MAbs E60, 87.1 or E87 ...
In an attempt to generate broadly cross-reactive, neutralizing monoclonal antibodies (MAbs) to simia...
Non-human primates (NHPs) are the only animal model that are used to evaluate the protection efficac...
Each panel represents neutralization of macaques infected with the same virus: a) SIVMneCL8; b) SIVM...
A major goal of efforts to develop a vaccine to prevent HIV-1 infection is induction of broadly cros...
<p>(A) RhCMVIL-10-binding antibodies were analyzed throughout the immunization schedule (<a href="ht...
(A) Standard neutralization regression analyses are shown for ITS01 (upper) and ITS06.02 (lower) fro...
<p>A. Wild-type virions (200 p.f.u.) were incubated with mAbs as shown (2h, 37°C) then plaque-assaye...
Summary: Induction of broadly neutralizing antibodies (bnAbs) that target HIV-1 envelope (Env) is a ...
<p>(A) Sera collected at 10 days post-last vaccination were tested for neutralization of MERS-CoV in...
<p>(<b>a–c</b>) Human IgG1 antibody 503 (1 µg/mL) demonstrates binding to HEK-293 cells transiently ...
<p>A) FACS data overlay of individually sorted CVNbs-specific B cells (multicolored) from 4 SIV-infe...
<p><b>A</b>: Binding of Fab m43 to recombinant gp140s, gp120s and gp41Fc fusion protein. <b>B</b>: B...
Protection from immunodeficiency virus challenge in nonhuman primates (NHPs) by a first-generation H...
<p>Macaque samples (analyzed as purified IgG) are arranged in the left-most column according to the ...
<p><b>A.</b> Fusion loop-specific mouse MAb 4G2 was incubated at 1 µg/mL with MAbs E60, 87.1 or E87 ...
In an attempt to generate broadly cross-reactive, neutralizing monoclonal antibodies (MAbs) to simia...
Non-human primates (NHPs) are the only animal model that are used to evaluate the protection efficac...
Each panel represents neutralization of macaques infected with the same virus: a) SIVMneCL8; b) SIVM...
A major goal of efforts to develop a vaccine to prevent HIV-1 infection is induction of broadly cros...
<p>(A) RhCMVIL-10-binding antibodies were analyzed throughout the immunization schedule (<a href="ht...
(A) Standard neutralization regression analyses are shown for ITS01 (upper) and ITS06.02 (lower) fro...
<p>A. Wild-type virions (200 p.f.u.) were incubated with mAbs as shown (2h, 37°C) then plaque-assaye...
Summary: Induction of broadly neutralizing antibodies (bnAbs) that target HIV-1 envelope (Env) is a ...
<p>(A) Sera collected at 10 days post-last vaccination were tested for neutralization of MERS-CoV in...
<p>(<b>a–c</b>) Human IgG1 antibody 503 (1 µg/mL) demonstrates binding to HEK-293 cells transiently ...